PeptiDream announces strategic partnership and license option agreement with Amolyt Pharma


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ PeptiDream announces strategic partnership and license option agreement with Amolyt Pharma
This collaboration will help both companies to work together to test and further optimize PeptiDream’s Growth Hormone Receptor Antagonist“GHRA” peptide candidates

PeptiDream Inc., a public Kanagawa-based biopharmaceutical company announced that it has entered into a strategic partnership and license option agreement with Lyon, FRANCE-based Amolyt Pharma, whereby both companies will work together to test and further optimize PeptiDream’s Growth Hormone Receptor Antagonist“GHRA” peptide candidates, with the goal of selecting a clinical candidate for development in acromegaly, a rare endocrine disorder with serious medical complications, to which Amolyt has an option to license the candidates for future clinical development.

Under the terms of the agreement, PeptiDream will be eligible for certain payments associated with the licensing, development, and commercial success of any GHRA product(s), as well as be eligible for certain royalties on future net sales.

“We are pleased to partner with PeptiDream, a leading Japanese biopharmaceutical company with an impressive technology platform for the design of new therapeutic peptides, and whose strategic partners include world class pharmaceutical companies. The potential expansion of our pipeline into acromegaly, where significant unmet needs persist, represents a perfect strategic fit for Amolyt. Given our extensive experience in developing therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases, including our lead clinical candidate, AZP-3601, for hypoparathyroidism, we believe we have the expertise to successfully bring a promising therapy to acromegaly patients in need,” said Thierry Abribat PhD, CEO of Amoylt Pharma.

“We believe Amolyt Pharma is the ideal partner to lead the development of our GHRA peptide candidates and potentially bring an improved treatment paradigm to patients suffering from acromegaly. We are impressed by their therapeutic peptide development capabilities and we are confident in entrusting them with advancing this potentially important asset. We look forward to a mutually beneficial partnership.” said Patrick C. Reid PhD, President & CEO of PeptiDream.

Tags : #PeptiDreamInc #LatestNewsonPeptiDreamInc9thDec #LatestPharmaNews9thDec #LatestPharmaCollaboration9thDec #AmolytPharma #LatestNewsonAmolytPharma9thDec

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026